HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

ceftobiprole medocaril

a ceftobiprole prodrug
Networked: 21 relevant articles (4 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Flamm, Robert K: 3 articles (07/2014 - 01/2010)
2. Singh, Kavindra V: 2 articles (06/2012 - 09/2007)
3. Murray, Barbara E: 2 articles (06/2012 - 09/2007)
4. Melton, John L: 2 articles (03/2012 - 01/2010)
5. Fernandez, Jeffrey: 2 articles (03/2012 - 01/2010)
6. Abbanat, Darren: 2 articles (03/2012 - 01/2010)
7. Strauss, Richard S: 2 articles (03/2012 - 03/2008)
8. Noel, Gary J: 2 articles (03/2012 - 03/2008)
9. Amsler, Karen: 2 articles (03/2012 - 03/2012)
10. Del Pozo, Jose L: 2 articles (01/2010 - 11/2008)

Related Diseases

1. Pneumonia (Pneumonitis)
2. Infection
3. Urinary Tract Infections (Urinary Tract Infection)
4. Mediastinitis
5. Ventilator-Associated Pneumonia (Pneumonia, Ventilator Associated)
12/01/2015 - "Ceftobiprole medocaril is a fifth-generation cephalosporin approved in Europe as single-agent therapy for hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). "
07/01/2014 - "Ceftobiprole medocaril is a newly approved drug in Europe for the treatment of hospital-acquired pneumonia (HAP) (excluding patients with ventilator-associated pneumonia but including ventilated HAP patients) and community-acquired pneumonia in adults. "
01/01/2006 - "Ceftobiprole medocaril is currently in phase III trials for complicated skin and skin structure infections due to MRSA, and nosocomial pneumonia (including ventilator-associated pneumonia) due to suspected or proven MRSA, and community-acquired pneumonia. "
01/01/2010 - "The US Food and Drug Administration granted ceftobiprole medocaril fast-track status in 2003 for the treatment of complicated skin infections and skin structure infections due to methicillin-resistant staphylococci, and subsequently extended this to treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia due to suspected or proven methicillin-resistant Staphylococcus aureus."
01/01/2007 - "Ceftobiprole medocaril is a cephalosporin prodrug that is under investigation for treatment of complicated skin and skin-structure infections (cSSSIs) due to methicillin-resistant Staphylococcus aureus (MRSA) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia due to suspected or proven MRSA. "

Related Drugs and Biologics

1. Vancomycin
2. linezolid (Zyvox)
3. ceftobiprole
4. Cefazolin (Ancef)
5. Ceftriaxone (Ceftriaxon)
6. Ceftazidime (Fortum)
7. Daptomycin
8. beta-Lactamases (beta-Lactamase)
9. Ro 63-9141
10. cefepime (Maxipime)